Ranolazine dihydrochloride

Ranolazine is a piperazine derivative with cardioprotective activity. It reduces the late sodium current (I_Na) in mouse myocytes expressing the long QT syndrome 3 mutant sodium channel DKPQ, ventricular myocytes isolated from a canine model of heart failure, guinea pig ventricular myocytes exposed to hydrogen peroxide or anemone toxin-II, and HEK293 cells expressing human Na_v1.5 channels (IC₅₀s = 5.9-15 μM) as well as the late potassium current (I_Kr) in canine ventricular myocytes and HEK293 cells (IC₅₀s = 11.5 and 14.4 μM, respectively). Ranolazine also inhibits radioligand binding to α₁-, β₁-, and β₂-adrenergic receptors (K_is = 8.2-19.5, 1.4-8.6, and 0.5-14.8 μM, respectively). In vivo, ranolazine (480 μg/kg per min) reduces clofilium-induced prolongation of the QTc interval and Torsade de Pointes (TdP) in rabbits. Ranolazine also reduces interstitial collagen deposition as well as atrial natriuretic peptide (ANP; Item Nos. 24539 | 24276), connective tissue growth factor (CTGF), brain natriuretic peptide (BNP; ), and matrix metalloproteinase-2 (MMP-2) mRNA levels, and prevents left ventricular dilation in a mouse model of cardiotoxicity induced by doxorubicin .

White Crystalline Powder

treatment of angina and congestive heart failure

Ranolazine Dihydrochloride is an anti-ischemic agent which modulates myocardial metabolism. Antianginal.

Antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late I Na and I Kr currents.

Ranolazine is a derivative of anti-ischemic piperazine and acts as sodium (Na+)-current inhibitor. It has the potential to treat diastolic heart failure and helps in ameliorating myocardial diastolic function.

Desiccate at RT

[1] J C SHRYOCK  L B. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium[J]. British Journal of Pharmacology, 2009, 153 6: 1128-1132. DOI: 10.1038/sj.bjp.0707522
[2] RICHARD L VERRIER. Mechanisms of ranolazine’s dual protection against atrial and ventricular fibrillation.[J]. Europace, 2013, 15 3: 317-324. DOI: 10.1093/europace/eus380
[3] WEI-QUN WANG. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.[J]. Journal of Pharmacology and Experimental Therapeutics, 2008, 325 3: 875-881. DOI: 10.1124/jpet.108.137729
[4] CARLO G. TOCCHETTI. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction[J]. European Journal of Heart Failure, 2014, 16 4: 358-366. DOI: 10.1002/ejhf.50